Genomix Biotech Inc. is a privately held U.S. based company with operations in India through its sister concern Genomix Molecular Diagnostics Pvt. Ltd. focused in the development and commercialization of:

• In Vitro Molecular Diagnostics for infectious diseases of greatest need,
• Microarray, Gene Expression Analysis-based Diagnostics for Cancer, Diabetes, Cardiovascular diseases,
• Recombinant Biopharmaceuticals and Natural products for therapeutic intervention of disease processes and vaccines,
• Crucial products for biomedical research,
• Provide services with contract research work using recombinant and transgenics.

Viral, bacterial, fungal and parasitic infections can be diagnosed with greater accuracy and at early stages in a cost effective manner. Advances in immuno, PCR (Polymerase Chain Reaction), multiplexing, sequencing, micro-arrays and nanotechnology are leading to the emergence of of personalized medicine creating tremendous opportinities for molecular diagnostics. It will also play a major role in cancer diagnosis and treatment.

Genomix Biotech will develop and market Molecular Diagnostics products both in India and abroad. Since the isothermall PCR can be made currently more affordable and the reagents can be made in India at a much lower cost, the company will set up isothermal PCRs in clinical laboratories at hospitals in several cities and market the reagents. After the preliminary introduction of the products, the company will market the products by partnering with one of the leading diagnostic companies. Genomix Biotech will be primarily involved in the discovery and development of cost-effective new diagnostic tests for a number of infectious diseases using new markers or a meaningful combination of existing markers that are strongly correlated with either the pathogenics or the prognosis of a particular disease. Studies have demonstrated that molecular diagnostic arrays can be used successfully to identify new biological markers associated with a particular disease and also to monitor patient response to therapy. Ultimately, successful assays of this type will contribute directly to therapies that are more cost-effective, timely and ultimately lead to successful therapeutic outcomes.

Some of the important diagnostics currently available with Genomix Biotech are:

• Human Papilloma Virus (HPV)
• Dengue
• Chickenguniya
• Tuberculosis
• Malaria

Microarray technology is an emerging class of clinical laboratory tests that predict disease progression and treatment response where physicians and patients can make successful treatment choices.

Cancer is a major disease that causes substantial suffering, death, and cost worldwide. Genomix Biotech believes that a greater understanding of the biology of tumors and utility of biomarkers for improved preclinical screening, diagnosis, disease staging and monitoring of treatment will move us closer to realizing the goals of personalized medicine. Our team of talented and experienced scientists and professionals will work diligently towards providing cancer researchers and clinicians with tools to determine the proper drug for an individual patient at a given stage of disease or treatment.

Genetic analysis of tumors is the key to truly improving the treatment of cancer patients.

To better understand and therefore treat cancer, insight into the complex molecular characteristics of the disease is essential. Deeper knowledge of a tumor's gene expression profile is clinically significant as it can be used to predict the ability of an individual tumor to metastasize or its response to anti-cancer drugs. In addition, more insight into a range of tumor properties may reveal new drug targets or specific prognostic patterns that can be used in drug development.

Genomix Biotech is developing high-quality diagnostic methods, using microarray gene expression profiling, for analyzing tumor samples and determining the tumor's specific properties. This strategy can result in a reliable prediction whether an individual patient is at high or low risk of disease recurrence. In addition, Genomix Biotech also offers services aimed at identifying the primary tumor in patients diagnosed with distant metastasis.

Genomix Biotech's innovative, yet robust, methods provide physicians and patients with crucial information for determining the optimal treatment plan based on personalized gene expression information, significantly enhancing the chances for success. At the same time, our tests enable physicians to minimize their patient's morbidity and expenses associated with other more invasive diagnostic procedures.

The increasing understanding of the genetic basis of disease will fuel the development of gene expression profiling as an important tool in diagnosis, prognosis and the generation of novel drug targets. Genomix Biotech strives to offer state of the art DNA microarray technology and analytical approaches to physicans and pharmaceutical companies, improving the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.